Article Text

This article has a correction. Please see:

Download PDFPDF
Medicines update

Statistics from

The points below highlight changes in marketing authorisations (MAs) that may have a significant impact on veterinary surgeons’ prescribing decisions.

New marketing authorisations

New marketing authorisations relevant to veterinary surgeons in the UK that were issued or published in May 2019 are listed in Table 1.

View this table:
Table 1: Marketing authorisations issued and/or published in May 2019

Of those products listed, the VMD draws attention to:

• Laxatract 667 mg/ml syrup for dogs and cats is the first veterinary-authorised product containing the active substance lactulose. The product is indicated for use in dogs and cats as follows: ‘For the treatment of constipation (eg, due to intestinal atony after surgery, hairballs, massive intestinal contents). For the symptomatic treatment of disease conditions which require facilitated defecation (eg, partial obstructions due to for example tumours and fractures, rectal diverticulum, proctitis and poisoning).’

Table 1 also indicates where a public assessment report …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Letters and notices
    BMJ Publishing Group Limited